Search research articles
Contact Us
Filters
Showing results (71-80 of 82) with videos related to
Page
of 9
Sort By:
Journal of Neuroinflammation
|
December 13, 2024
Tyro3 and Gas6 are associated with white matter and myelin integrity in multiple sclerosis
Igal Rosenstein, Lenka Novakova, Hlin Kvartsberg, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
October 27, 2020
Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing-remitting multiple sclerosis: an observational study
Christina Zhukovsky, Sofia Sandgren, Thomas Silfverberg, et al.
Clinical Chemistry and Laboratory Medicine
|
August 22, 2025
Validation of a plasma GFAP immunoassay and establishment of age-related reference values: bridging analytical performance and routine implementation
Burak Arslan, Ulf Andreasson, Elzbieta Rembeza, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
October 6, 2012
Serum levels of LIGHT in MS
Clas Malmeström, Alan Gillett, Margareta Jernås, et al.
Journal of Neuroimmunology
|
April 8, 2017
Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying malignancies
Radu Constantinescu, David Krýsl, Kerstin Andrén, et al.
Neurology
|
October 21, 2016
Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy
Jonatan Salzer, Rasmus Svenningsson, Peter Alping, et al.
Brain Communications
|
May 14, 2026
A novel multiplexed biomarker panel reveals key molecular pathways in progressive multiple sclerosis
Christina N Heiss, Lenka Novakova, Markus Axelsson, et al.
European Journal of Neurology
|
July 31, 2023
The impact of hybrid immunity on immune responses after SARS-CoV-2 vaccination in persons with multiple sclerosis treated with disease-modifying therapies
Monika Rabenstein, Olivia G Thomas, Giorgia Carlin, et al.
Journal of the Neurological Sciences
|
June 19, 2022
MIF in the cerebrospinal fluid is decreased during relapsing-remitting while increased in secondary progressive multiple sclerosis
Simone Hjæresen, Tobias Sejbaek, Markus Axelsson, et al.
The Lancet. Neurology
|
July 16, 2022
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial
Anders Svenningsson, Thomas Frisell, Joachim Burman, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 82) with videos related to
Sort By:
Page
of 9
Journal of Neuroinflammation
|
December 13, 2024
Tyro3 and Gas6 are associated with white matter and myelin integrity in multiple sclerosis
Igal Rosenstein, Lenka Novakova, Hlin Kvartsberg, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
October 27, 2020
Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing-remitting multiple sclerosis: an observational study
Christina Zhukovsky, Sofia Sandgren, Thomas Silfverberg, et al.
Clinical Chemistry and Laboratory Medicine
|
August 22, 2025
Validation of a plasma GFAP immunoassay and establishment of age-related reference values: bridging analytical performance and routine implementation
Burak Arslan, Ulf Andreasson, Elzbieta Rembeza, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
October 6, 2012
Serum levels of LIGHT in MS
Clas Malmeström, Alan Gillett, Margareta Jernås, et al.
Journal of Neuroimmunology
|
April 8, 2017
Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying malignancies
Radu Constantinescu, David Krýsl, Kerstin Andrén, et al.
Neurology
|
October 21, 2016
Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy
Jonatan Salzer, Rasmus Svenningsson, Peter Alping, et al.
Brain Communications
|
May 14, 2026
A novel multiplexed biomarker panel reveals key molecular pathways in progressive multiple sclerosis
Christina N Heiss, Lenka Novakova, Markus Axelsson, et al.
European Journal of Neurology
|
July 31, 2023
The impact of hybrid immunity on immune responses after SARS-CoV-2 vaccination in persons with multiple sclerosis treated with disease-modifying therapies
Monika Rabenstein, Olivia G Thomas, Giorgia Carlin, et al.
Journal of the Neurological Sciences
|
June 19, 2022
MIF in the cerebrospinal fluid is decreased during relapsing-remitting while increased in secondary progressive multiple sclerosis
Simone Hjæresen, Tobias Sejbaek, Markus Axelsson, et al.
The Lancet. Neurology
|
July 16, 2022
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial
Anders Svenningsson, Thomas Frisell, Joachim Burman, et al.
Page
of 9